-
Tytuł:
-
Alnus hirsuta (Spach) Rupr. Attenuates Airway Inflammation and Mucus Overproduction in a Murine Model of Ovalbumin-Challenged Asthma.
-
Autorzy:
-
Lee BW; Functional Biomaterial Research Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup-si, South Korea.; Department of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Chonnam National University, Gwangju, South Korea.
Ha JH; Functional Biomaterial Research Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup-si, South Korea.; Department of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Chonnam National University, Gwangju, South Korea.
Ji Y; Functional Biomaterial Research Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup-si, South Korea.
Jeong SH; Functional Biomaterial Research Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup-si, South Korea.
Kim JH; Functional Biomaterial Research Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup-si, South Korea.
Lee J; Functional Biomaterial Research Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup-si, South Korea.
Park JY; Functional Biomaterial Research Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup-si, South Korea.
Kwon HJ; Functional Biomaterial Research Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup-si, South Korea.
Jung K; Functional Biomaterial Research Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup-si, South Korea.
Kim JC; Department of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Chonnam National University, Gwangju, South Korea.
Ryu YB; Functional Biomaterial Research Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup-si, South Korea.
Lee IC; Functional Biomaterial Research Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup-si, South Korea.
-
Źródło:
-
Frontiers in pharmacology [Front Pharmacol] 2021 Feb 10; Vol. 12, pp. 614442. Date of Electronic Publication: 2021 Feb 10 (Print Publication: 2021).
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: [Lausanne : Frontiers Media]
-
References:
-
Chem Pharm Bull (Tokyo). 2010 Feb;58(2):238-41. (PMID: 20118587)
Clin Exp Allergy. 2011 Feb;41(2):149-59. (PMID: 21121982)
J Ethnopharmacol. 2017 Sep 14;209:108-115. (PMID: 28735728)
Phytomedicine. 2019 Aug;61:152835. (PMID: 31035047)
Curr Opin Pharmacol. 2010 Jun;10(3):236-45. (PMID: 20591736)
Korean J Intern Med. 2005 Dec;20(4):275-83. (PMID: 16491824)
J Allergy Clin Immunol Pract. 2014 Nov-Dec;2(6):645-8; quiz 649. (PMID: 25439351)
Biol Pharm Bull. 2007 Apr;30(4):810-3. (PMID: 17409527)
Int Immunopharmacol. 2016 Jan;30:129-136. (PMID: 26679675)
Phytomedicine. 2018 May 15;44:74-84. (PMID: 29895495)
J Agric Food Chem. 2017 Jun 7;65(22):4472-4483. (PMID: 28502165)
Am J Respir Crit Care Med. 2013 Jan 1;187(1):42-8. (PMID: 23155143)
BMJ. 2014 Jul 16;349:g4623. (PMID: 25035241)
J Pharmacol Pharmacother. 2013 Dec;4(Suppl 1):S94-8. (PMID: 24347992)
Int Immunopharmacol. 2017 Oct;51:158-164. (PMID: 28843179)
Antioxidants (Basel). 2020 Jan 24;9(2):. (PMID: 31991647)
Int Immunopharmacol. 2018 Aug;61:204-214. (PMID: 29890414)
Mol Med Rep. 2015 Sep;12(3):4640-4646. (PMID: 26063078)
Clin Chest Med. 2019 Mar;40(1):29-50. (PMID: 30691715)
Br J Pharmacol. 2005 Oct;146(3):378-88. (PMID: 16025135)
Int Immunopharmacol. 2019 Sep;74:105706. (PMID: 31254955)
Sci Total Environ. 2014 Nov 1;497-498:10-17. (PMID: 25112820)
Int Immunopharmacol. 2015 May;26(1):174-80. (PMID: 25662753)
EBioMedicine. 2017 Feb;15:137-149. (PMID: 28024734)
Phytomedicine. 2019 Apr;57:84-94. (PMID: 30668326)
Nat Rev Drug Discov. 2002 Jan;1(1):77-84. (PMID: 12119612)
Nanotoxicology. 2016;10(4):445-52. (PMID: 26472121)
Respir Res. 2010 Jun 21;11:82. (PMID: 20565957)
Phytochemistry. 2020 May;173:112292. (PMID: 32062198)
Exp Dermatol. 2010 Aug;19(8):e37-43. (PMID: 19849716)
Dis Model Mech. 2008 Nov-Dec;1(4-5):213-20. (PMID: 19093027)
Medicine (Baltimore). 2017 Feb;96(8):e6147. (PMID: 28225496)
Curr Allergy Asthma Rep. 2017 Jul;17(7):43. (PMID: 28555329)
Int Immunopharmacol. 2019 Mar;68:124-130. (PMID: 30622029)
Clin Exp Allergy. 2015 Dec;45(12):1812-22. (PMID: 26245530)
J Pharm Biomed Anal. 2015 Mar 25;107:159-67. (PMID: 25594894)
Phytomedicine. 2017 Aug 15;32:1-7. (PMID: 28732802)
Int Immunopharmacol. 2012 May;13(1):126-34. (PMID: 22465960)
Int Immunopharmacol. 2017 Dec;53:49-55. (PMID: 29035815)
J Allergy Clin Immunol. 2013 Dec;132(6):1322-36. (PMID: 24139829)
Phytomedicine. 2019 Apr;57:305-314. (PMID: 30807985)
Biomed Pharmacother. 2019 Jan;109:1024-1031. (PMID: 30551352)
PLoS One. 2015 Feb 06;10(2):e0117524. (PMID: 25658604)
Phytomedicine. 2018 Dec 1;51:29-38. (PMID: 30466625)
Antioxidants (Basel). 2020 Apr 01;9(4):. (PMID: 32244835)
-
Contributed Indexing:
-
Keywords: Alnus hirsuta (spach) Rupr.; airway inflammation; allergic asthma; mitogen-activated protein (MAP) kinase; mucus overproduction; nuclear factor-kappa B
-
Entry Date(s):
-
Date Created: 20210301 Latest Revision: 20210303
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC7902870
-
DOI:
-
10.3389/fphar.2021.614442
-
PMID:
-
33643046
-
Alnus hirsuta (Spach) Rupr. (AH), a member of the Betulaceae family, is widely used in Eastern Asia of as a source of medicinal compounds for the treatment of hemorrhage, diarrhea, and alcoholism. In this study, we investigated the protective effects of a methanolic extract of AH branches against airway inflammation and mucus production in tumor necrosis factor (TNF)-α-stimulated NCI-H292 cells and in an ovalbumin (OVA)-challenged allergic asthma mouse model. Female BALB/c mice were injected with OVA (40 μg) and aluminum hydroxide (2 mg) on days 0 and 14 to induce allergic airway inflammation. The mice were then challenged with 1% OVA from days 21-23. Mice were treated with AH (50 and 100 mg/kg/day; 2% DMSO) or dexamethasone (positive control; 3 mg/kg/day) from days 18-23. AH treatment effectively attenuated airway resistance/hyperresponsiveness and reduced levels of T helper type 2 (Th2) cytokines, eotaxins, and number of inflammatory cells in bronchoalveolar lavage fluid, and immunoglobulin E in serums of OVA-challenged mice. In histological analysis, AH treatment significantly inhibited airway inflammation and mucus production in OVA-challenged mice. AH treatment downregulated the phosphorylation of I kappa B-alpha, p65 nuclear factor-kappa B (p65NF-κB), and mitogen-activated protein kinases with suppression of mucin 5AC (MUC5AC) in lung tissue. Moreover, AH treatment decreased the levels of pro-inflammatory cytokines and Th2 cytokines, as well as MUC5AC expression, and inhibited the phosphorylation of p65NF-κB in TNF-α-stimulated NCI-H292 cells. These results indicate that AH might represent a useful therapeutic agent for the treatment of allergic asthma.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Lee, Ha, Ji, Jeong, Kim, Lee, Park, Kwon, Jung, Kim, Ryu and Lee.)
